Faeth Therapeutics, Inc <FTH.O>: Oppenheimer initiates coverage with outperform rating; price target $60
FTH•Related News
Perma-Fix Q2 FY26 net loss widens to $(6) million; revenue totals $13 million
PESI•
Google rivals line up seeking damages after record $1 billion EU fine
GOOGL•
Ecolab raises annual profit forecast on pricing, high-tech demand
ECL•
Summit State Bank posts Q2 loss on higher credit provisions
SSBI•
Bicara Therapeutics Announces Appointments Of Jeremy Bender And Christy Oliger To Board Of Directors
BCAX•